More progress in COVID-19 treatment, vaccine as scientists get deeper understanding of virus

More progress in COVID-19 treatment, vaccine as scientists get deeper understanding of virus
A man wearing a face mask sits in a tram at Manchester Victoria Railway Station in Manchester, Britain, on June 15, 2020. (Photo by Jon Super/Xinhua) Special: Battle Against Novel Coronavirus With the COVID-19 pandemic imposing huge impact on people’s daily life in Britain and other parts of the world, scientists are racing against time to get deeper understanding of the novel coronavirus while accelerating the development of new treatments and vaccines.Through the British government backed RECOVERY (Randomized Evaluation of COVID-19 Therapy) trial, researchers have found that low-dose dexamethasone (a steroid treatment) reduces death in hospitalized patients with severe respiratory complications of COVID-19.In this trial, a total of 2,104 patients were randomized to receive 6 mg of dexamethasone once per day (either by mouth or by intravenous injection) for 10 days and were compared with 4,321 patients randomized to usual care alone, according to the University of Oxford, whose researchers are leading the trial.Dexamethasone reduced deaths by one third in ventilated patients and by one fifth in other patients receiving oxygen only, but there was no benefit among those patients who did not require respiratory support, the results showed.Based on these results, researchers believe that one death would be prevented by treatment of around eight ventilated patients or around 25 patients requiring oxygen alone.”Dexamethasone is the first drug to be shown to improve survival in COVID-19,” said Peter Horby, professor of emerging infectious diseases in the Nuffield Department of Medicine, University of Oxford, and one of the chief investigators for the trial.People queue outside a Primark store in central Manchester, Britain, June 15, 2020. (Photo by Jon Super/Xinhua)”The survival benefit is clear and large in those patients who are sick enough to require oxygen treatment, so dexamethasone should now become standard of care in these patients. Dexamethasone is inexpensive, on the shelf, and can be used immediately to save lives worldwide,” he added.Aside from treatments, researchers in Britain are also making progress in vaccine development.A team at the University of Oxford has initiated clinical trial of its vaccine candidate in April.On Monday, the Imperial College London also announced that a new coronavirus vaccine developed by its researchers are set to start clinical trial this week.A passenger arrives at the Brussels Airport for a flight in Zaventem, Belgium, June 15, 2020. (Xinhua/Zheng Huansong)The vaccine programs respectively at Oxford and the Imperial College London are at the forefront of Britain’s vaccine development efforts. The British government has announced that it will provide funding for these two programs.The vaccine developed at the Imperial is based on a new self-amplifying RNA technology. Researchers will test whether it is well-tolerated and produces an effective immune response against COVID-19 in humans.Over the coming weeks, 300 healthy participants will receive two doses of the vaccine. If the vaccine is safe and shows a promising immune response in humans, then larger Phase III trials would be planned to begin later in the year with around 6,000 healthy volunteers to test its effectiveness, according to the Imperial.”From a scientific perspective, new technologies mean we have been able to get moving on a potential vaccine with unprecedented speed,” said professor Robin Shattock from the Department of Infectious Disease at Imperial and who is leading the work.”We’ve been able to produce a vaccine from scratch and take it to human trials in just a few months — from code to candidate — which has never been done before with this type of vaccine. If our approach works and the vaccine provides effective protection against disease, it could revolutionize how we respond to disease outbreaks in future,” he said.A man wearing a mask gets off a tram at Manchester Victoria Railway Station in Manchester, Britain, on June 15, 2020. (Photo by Jon Super/Xinhua)

发表评论

电子邮件地址不会被公开。 必填项已用*标注

Related Post

金融类四大证书你更适合考哪个吗?哪个含金量高呢?_进入银行金融类四大证书你更适合考哪个吗?哪个含金量高呢?_进入银行

金融类四大证书你更适合考哪个吗?哪个含金量高呢?_进入银行金融类四大证书你更适合考哪个吗?哪个含金量高呢?金融作业入门门槛较低,但一向以高收入而闻名。想要进入金融作业的你,考哪个证书更适宜呢?挑选一:基金从业资历证基金从业人员必备的作业资历证书。除了基金公司外,基金相关结构的从业人员都需求考取并请求基金从业资历,包含:商业银行(含在

36氪首发 – 新锐美瞳品牌MOODY完成6000万两轮融资,高瓴、经纬分别领投36氪首发 – 新锐美瞳品牌MOODY完成6000万两轮融资,高瓴、经纬分别领投

36氪首发|新锐美瞳品牌MOODY完成6000万两轮融资,高瓴、经纬分别领投原标题:36氪首发|新锐美瞳品牌MOODY完成6000万两轮融资,高瓴、经纬分别领投36氪获悉,新国货美瞳品牌MOODY近日完成共计6000万元的两轮融资,其中天使轮由高瓴资本资本领投,梅花创投跟投;A轮由经纬中国领投,源码资本跟投,高瓴

前海联合基金何杰:下半年A股仍是全球范围极具吸引力的权益资产 _ 东方财富网前海联合基金何杰:下半年A股仍是全球范围极具吸引力的权益资产 _ 东方财富网

前海联合基金何杰:下半年A股仍是全球范围极具吸引力的权益资产_东方财富网摘要【前海联合基金何杰:下半年A股仍是全球规模极具吸引力的权益财物】何杰以为,下半年A股仍是全球规模极具吸引力的权益财物,高质量开展依然是中长时刻实体经济和金融商场的主线,新兴工业、科技职业,以及一些存量周期龙头仍将源源不断地发明价值报答。(证券时报)前海联合价